resTORbio
Edit

resTORbio

https://www.restorbio.com/
Last activity: 26.01.2018
Active
resTORbio is an advanced clinical stage company, developing medicines to treat aging-related diseases and conditions.
Followers
838
Website visits
32.8K /mo.
Mentions
10
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $40M
Founded date: 2016

Investors 1

Funding Rounds 1

DateSeriesAmountInvestors
01.12.2017Series B$40M-

Mentions in press and media 10

DateTitleDescription
26.01.2018Term Sheet — Friday, January 26IPO HYPE Happy Friday, Term Sheet readers, Paid Content You can't secure what you can't see From ExtraHop Market conditions signal a strong year for IPOs, according to SVB’s latest State of the Market report. There should be a steady stream...
26.01.2018resTORbio Announces Initial Public Offering PricingresTORbio, Inc., a Boston, MA-based clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases, announced the pricing of its initial public off...
16.01.2018Term Sheet — Tuesday, January 16CRYPTO ROADBLOCKS Good morning, Term Sheet readers. Paid Content You can't secure what you can't see From ExtraHop Metropolitan Bank Holding Corp, which is used by cryptocurrency companies and investment firms for wire transfers and deposit...
02.01.2018Term Sheet — Tuesday, January 2UBER’S RESET Happy New Year, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop UBER’S BIG DAY: SoftBank agreed to invest more than $7 billion in Uber for a 15% stake in the tech giant. According to me...
01.12.2017Term Sheet — Friday, December 1DONE IN THE DARK Good morning, Term Sheet readers. Paid Content How can you protect what you can't see? From ExtraHop Over the years, these people say, Pishevar seemed to take a liking to Geidt, following her around at company events, and a...
01.12.2017resTORbio Completes $40M Series B FinancingresTORbio, Inc., a Boston, MA-based clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases, completed a $40m Series B financing round. The ...
30.11.2017resTORbio Inks $40M Series B Funding BOSTON, MA, resTORbio today announced the completion of an oversubscribed $40 million Series B financing round. >> Click here for more funding data on resTORbio >> To export resTORbio funding data to PDF and Excel, click her...
30.11.2017resTORbio Raises $40 MillionBOSTON--(BUSINESS WIRE)--resTORbio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced the completion of an ov...
30.11.2017Novartis-backed resTORbio raises $40M for aging disease trialsBoston biotech resTORbio has pocketed another $40 million from a second-round financing that it hopes gives it enough cash to move its lead candidate for respiratory tract infections in elderly patients into phase 3. The latest round brings...
30.11.2017Rock Springs Capital Joins $40M Series B for ResTORbioBOSTON--(BUSINESS WIRE)--resTORbio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced the completion of an ov...

Reviews 0

Sign up to leave a review

Sign up Log In